RxDoctor Payments Data

Tudor Scridon, MD

Cardiovascular Disease · Vero Beach, FLNPI 1407022395

Payments from drug & device makers

$13,389in general payments, 2019–2025

Across 403 payments — averaging $33.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Abbott$1K
  • Amgen$820
  • Novartis$810
  • Pfizer$786
  • Boehringer Ingelheim$772
  • plus $8K from 36 others

What the payments were for

  • Travel & lodging$3703%
  • Food & beverage$12,78796%
  • Education$2312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,389 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,020,906
Medicare patients
1,031
Services billed
9,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban740$703,117
EntrestoSacubitril/Valsartan289$271,749
OzempicSemaglutide155$194,778
JardianceEmpagliflozin182$159,579
XareltoRivaroxaban99$101,901
MounjaroTirzepatide44$49,794
Repatha SureclickEvolocumab47$41,075
FarxigaDapagliflozin Propanediol42$36,517
Repatha SyringeEvolocumab49$33,908
WegovySemaglutide13$24,234
NexlizetBempedoic Acid/Ezetimibe22$15,085
VerquvoVericiguat19$12,343
Nebivolol Hcl206$11,793
Rosuvastatin Calcium722$11,539
TrulicityDulaglutide12$11,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$786$703,117740 claims
NovartisEntresto$810$271,749289 claims
Novo NordiskOzempic, Wegovy$327$219,012168 claims
Boehringer IngelheimJardiance$772$159,579182 claims
Johnson & JohnsonXarelto$166$101,90199 claims
Lilly USA, LLCMounjaro, Trulicity$57$61,02156 claims
AstraZenecaFarxiga, Crestor$601$42,12054 claims
Esperion Therapeutics, Inc.Nexlizet$483$15,08522 claims
MerckVerquvo$666$12,34319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →